SCHEMBL5389745

SCHEMBL5389745

CN(Cc1cccc(-c2ccc(CC3SC(=O)NC3=O)cc2)c1)C(=O)c1ccc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.55
PPARG P37231 8/20 0.49
HSD17B2 P37059 6/20 0.47
HSD17B1 P14061 4/20 0.47
MPC2 O95563 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2C9 P11712 1/20 0.44
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762215 0.94 FFAR1 (0.54) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5391778 0.93 HSD17B2 (0.53) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5761160 0.92 FFAR1 (0.50) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5762442 0.92 FFAR1 (0.50) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5399098 0.92 FFAR1 (0.59) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5392724 0.91 FFAR1 (0.52) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5760239 0.91 HSD17B2 (0.56) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5760195 0.90 FFAR1 (0.52) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL6184172 0.90 FFAR1 (0.59) FFAR1PPARGHSD17B2HSD17B1MPC2
SCHEMBL5762182 0.89 FFAR1 (0.47) FFAR1PPARGHSD17B2HSD17B1MPC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US claimed
US-7294639-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-11-13 US disclosed
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-02-22 US disclosed
US-7122564-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-17 US disclosed
EP-1458697-B1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RES & DEV (FR) 2006-09-06 EP disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
EP-1458697-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS Galderma Research & Development, S.N.C. (FR) 2004-09-22 EP disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed
WO-2003055867-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors PPARG, PPARA, PPARD FFAR1 13/4885PPARG 1/4885HSD17B2 278/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD FFAR1 13/4885PPARG 1/4885HSD17B2 278/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD FFAR1 10/4885PPARG 1/4885HSD17B2 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.